ADC Therapeutics (ADCT) Revenue (2019 - 2023)
Historic Revenue for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to $14.5 million.
- ADC Therapeutics' Revenue fell 8101.05% to $14.5 million in Q3 2023 from the same period last year, while for Dec 2023 it was $52.8 million, marking a year-over-year decrease of 9992.46%. This contributed to the annual value of $209908.0 for FY2022, which is 9931.25% down from last year.
- According to the latest figures from Q3 2023, ADC Therapeutics' Revenue is $14.5 million, which was down 8101.05% from $19.3 million recorded in Q2 2023.
- ADC Therapeutics' 5-year Revenue high stood at $69.8 billion for Q4 2022, and its period low was $145.0 during Q3 2020.
- In the last 5 years, ADC Therapeutics' Revenue had a median value of $13.1 million in 2021 and averaged $4.7 billion.
- As far as peak fluctuations go, ADC Therapeutics' Revenue plummeted by 8988.14% in 2020, and later surged by 41033499700.18% in 2022.
- Quarter analysis of 5 years shows ADC Therapeutics' Revenue stood at $222.0 in 2019, then crashed by 34.68% to $145.0 in 2020, then skyrocketed by 11631.03% to $17010.0 in 2021, then soared by 410334997.0% to $69.8 billion in 2022, then plummeted by 99.98% to $14.5 million in 2023.
- Its last three reported values are $14.5 million in Q3 2023, $19.3 million for Q2 2023, and $19.0 million during Q1 2023.